Non-Destructive Evaporation Technology Improves Crystallisation Control

Genevac has launched eXalt, a technology developed with partners in the field of pharmaceutical small molecule crystallisation.

eXalt has found application in laboratories that perform tasks including first-time crystallisation of amorphous forms, recrystallisation of samples that have only a few known forms, removing a hydrate, solvent screening studies to find the most suitable conditions to take forward in development, high-throughput co-crystallisation screens and studies to confirm stable isoforms.

eXalt enables a wide range of solvents and multiple actives to be evaporated all at the same slow rate, under the same conditions, giving the user outstanding control of the crystallisation process. This is achieved using a special holder that can be configured to slow the evaporation rate of each solvent, i.e. the more volatile solvents are impeded more and some solvents such as water need no restriction. The holder is then placed in the controlled conditions of a Genevac HT Series evaporator, which cycles the pressure over the samples to create a draw, achieving controlled, even evaporation. eXalt holders can accept up to 24 different samples, and 4, 8 or 12 holders can be placed in the evaporator, depending on size.

Genevac Ltd, +44 1473 240000, salesinfo@genevac.co.uk, www.genevac.com/exalt.